Publication number: 20040063937
Abstract: The invention relates to novel N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives of the general formula (1) wherein the sum of (m+p) together is 0, 1, 2 or 3; n and q are independently of each other 0 or 1, and the sum of (m+p+q) together is 1, 2, 3 or 4; R1 is hydrogen, halogen, alkoxy, haloalkyl, haloalkoxy or alkyl; R2 is hydrogen, C1-C6-alkyl, C1-C6-haloalkyl or C1-C6-alkoxy; R2A is hydrogen, C1-C6-alkyl, C3-C4-alkenyl or C3-C4-alkynyl; each of R3, R4, R5 and R6 is, independently of the others, hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, hydroxy-C1-C6-alkyl or C1-C6-alkoxy-C1-C6-alkyl, or the ring members CR3R4 or CR5R6 or CR2R2A are independently of each other a carbonyl group (C═O) or a group C═S; X is C═O, C═S, S═O or O═S=O; Y is O, S, C═O, CH2A, —N(R8)—, —O—N(R8)—, —N(R8)—O— or NH—; R7 is hydrogen, C1-C4-alkyl, C3-C4-alkenyl, C3-C4-alkynyl, —CH2OR8, CH2SR8, —C(O)R8, —C(O)OR8,
Type:
Application
Filed:
June 25, 2003
Publication date:
April 1, 2004
Inventors:
Martin Eberle, Hugo Ziegler, Fredrik Cederbaum, Peter Ackermann, Anita Schnyder
Publication number: 20030207865
Abstract: This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.
Type:
Application
Filed:
October 23, 2001
Publication date:
November 6, 2003
Inventors:
Brian R. Dixon, Cedo M. Bagi, Catherine R. Brennan, David R. Brittelli, William H. Bullock, Jinshan Chen, William L. Collibee, Robert Dally, Jeffrey S. Johnson, Harold C. E. Kluender, William F. Lathrop, Peiying Liu, Carol Ann Mase, Aniko M. Redman, William J. Scott, Klaus Urbahns, Donald J. Wolanin
Patent number: 6613764
Abstract: The present invention provides a compound of formula (I) wherein a, b, c, d, and e, are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen. R7 and R8 are H or alkyl, R1 and R2 are H or alkyl, and R3 is a non-aromatic substituent. Substituent A is OH, NH2, or SH. Substituents B and B1 include amide and sulfonamide groups, which can be cyclic, acyclic, or amino acid derivatives. Alternatively, B and R′ together with the nitrogen to which they are bonded, and/or B′ and R2 together with the nitrogen to which they are bonded, define a heterocycle. The present invention further provides a pharmaceutical composition that includes a carrier and a therapeutically effective amount of at least one compound of the present invention.
Type:
Grant
Filed:
September 28, 2001
Date of Patent:
September 2, 2003
Assignee:
The United States of America as represented by the Department
of Health and Human Services
Inventors:
Ramnarayan S. Randad, John W. Erickson, Michael A. Eissenstat, Lucyna Lubkowska
© 2024 Justia
